JUL 18, 2021 3:34 PM PDT

COVID-19 Antibiotic No More Effective than Placebo

WRITTEN BY: Annie Lennon

Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, does not prevent COVID-19 symptoms from arising and may even increase a person's chance of hospitalization. The corresponding study was published in JAMA by researchers in California. 

Azithromycin is widely prescribed in the US and the rest of the world as a treatment for COVID-19. It was initially recommended on the basis that its anti-inflammatory properties may help prevent the progression of COVID-19 if used early on in the disease. 

"Most of the trials done so far with azithromycin have focused on hospitalized patients with pretty severe disease," said Catherine Oldenburg, lead author of the study. "Our paper is one of the first placebo-controlled studies showing no role for azithromycin in outpatients."

For the study, researchers recruited 263 people who tested positive for SARS-CoV-2 within seven days of enrolment. None of the patients were hospitalized at the beginning of the study. 

They were split into two treatment groups: the first group of 171 participants received a single, 1.2 gram oral dose of azithromycin, while the second group of 92 participants received an identical placebo. 

By day 14, the researchers found that there was no significant difference in the proportion of participants in either group who were symptom-free. In both groups, 50% of participants had no symptoms. By day 21, while patients given the antibiotic had been hospitalized, the same was true for none of the participants in the placebo group. 

The researchers conclude that their findings do not support the routine use of azithromycin for outpatients SARS-CoV-2 infection. The drug seemingly performs no better than a placebo in preventing COVID-19 symptoms from arising, as well as hospitalization from the disease. 

 

Sources: JAMAEurekAlert

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 01, 2022
Cannabis Sciences
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Study Finds CBD Does Not Reduce the Psychoactive High Caused by THC
Researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London found ...
DEC 11, 2022
Drug Discovery & Development
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
A monoclonal antibody drug known as rocatinlimab produced significant results in patients with moderate to severe atopic ...
DEC 21, 2022
Health & Medicine
Inhibiting a gene early on in type I diabetes could stop the disease in its tracks.
Inhibiting a gene early on in type I diabetes could stop the disease in its tracks.
Type I diabetes, or insulin-dependent diabetes, is a multigenic condition in which multiple genes are associated with th ...
DEC 30, 2022
Health & Medicine
New bacterial therapy approach to treat lung cancer
New bacterial therapy approach to treat lung cancer
Lung cancer is the leading cause of cancer-related mortality in the USA - the five-year relative survival rate is as low ...
JAN 10, 2023
Health & Medicine
Liver Let Die: Dying Liver Cells Disclose Cancer Diagnosis
Liver Let Die: Dying Liver Cells Disclose Cancer Diagnosis
The methylation patterns of DNA in the blood offer insight into the liver disease stage
JAN 10, 2023
Neuroscience
A Human Drug Improves the Recall of Lost Memories in Mice
A Human Drug Improves the Recall of Lost Memories in Mice
Staying up all night to prepare for an exam may not be much help to students, because memory can be impaired by many thi ...
Loading Comments...